Av
| Bolag | Omsättning jan-jun 2011 | Omsättning jan-jun 2010 | Resultat efter skatt jan-jun 2011 | Resultat efter skatt jan-jun 2010 |
| Sobi | 1 027 | 997 | 44,5 | -64 |
| Meda | 6 177 | 5 986 | 753 | 1 039 |
| Artimplant | 9,7 | 9,8 | -9,0 | -9,8 |
| Karo bio | 0 | 0 | -77,2 | -38,5 |
| Astrazeneca | 106 519 | 106 722 | 35,2 | 35,3 |
| Bioinvent | 115,6 | 36,1 | 27,8 | -60,7 |
| Aerocrine | 41,8 | 42,1 | -56,2 | -47,3 |
| Vitrolife | 88 | 73 | 10 | 9 |
Sobi, med en ökad omsättning, lyfte resultatet efter skatt över minus till 44,5 miljoner kronor i jämförelse med samma period 2010 då resultatet landade på -64 miljoner kronor. Bolaget genomförde en nyemission i våras och tog in 600 miljoner kronor och presenterade samtidigt sparplaner genom vilka bolaget ska spara 100 miljoner kronor årligen. I samband med sparplanerna rykte 70 arbetstillfällen.
Bioinvent nära dubblade sin omsättning under januari-juni i år och fick totalt in 115,6 miljoner kronor. En betydande skillnad från föregående år då omsättningen gick upp till 63,1 miljoner kronor. Bidragande till den ökande omsättningen under halvåret var bland annat en nyemission på 136 miljoner kronor som bolaget genomförde i juni samt milstolpbetalningar från bolagets samarbetspartners. Vid jämförelser av enbart andra kvartalet såg siffrorna dystrare ut. Jämfört med q2 2010 backade Bioinvent och förlusten ökade till -31,3 miljoner kronor från fjolårets resultat på -22,8 miljoner kronor.
Vitrolife ökade omsättningen med 29 procent under perioden januari-juni 2011 och drog totalt in 88 miljoner kronor. Det var en betydande ökning jämfört med samma halvår 2010 då omsättningen var 73 miljoner kronor. Resultat efter skatt blev i år 10 miljoner kronor. Även i den posten gick bolaget plus från samma period 2010 då resultatet var 9 miljoner kronor.
Meda ökade omsättningen, men lyckades inte öka resultat efter skatt i jämförelse med föregående år under perioden januari-juni. Årets resultat landade på 753 miljoner kronor, mot samma period förra året då resultatet blev 1 039 miljoner kronor.
Astrazenecas omsättning minskade relativt marginellt, till 106,5 miljarder kronor detta år jämfört med samma period förra året då den var 106,7 miljoner kronor. Även resultat efter skatt landade på en något lägre summa i år i jämförelse med föregående år.
Karo bios omsättning uteblev och uppgick, liksom förra året, till noll. Bolaget ökade därmed förlusten och resultat efter skatt blev -77,2 miljoner kronor under det första halvåret i år. En betydligt dystrare siffra en föregående år då resultatet var -38,5 miljoner kronor. Karo bio fick dock en efterlängtad utvecklingspartner till blodfettssänkaren eprotirome i slutet av april och ska sätta igång fas III-studier på läkemedelskandidaten.
"PCG - a professional full service CRO for your clinical trials.
Powered by Viedoc, globally trusted eCRF, keeping trials within budget and timelines" 
"Together with Zacco our clients achieve their business goals through the management of their intellectual property." 
"With our first class products and our committed and skilled colleagues we guarantee our customers the best support in the market, at no extra charge." 
"Our services in ligand-based and structure-based drug design is a cost-efficient alternative for smaller pharmaceutical companies" 
"We have a unique technological platform, built around 5HT-receptor antagonism, for the treatment of inflammation and pain"." 
"Our organisation value is to contribute to positioning Scandinavian healthcare and research in absolute world class." 
"APL provides high-quality services to Life Science. We are a Dedicated Partner from Discovery to Market." 
"Your work is important to us, we are committed to your success.
Innovative tools? Please download the Promega app." 
"Our aim is to be the best drug development partner to the biotechnology and pharmaceutical industry no matter where you are based." 
"Innovation takes place when biology meets engineering; ICT is an enabler to solve the needs for increased functionality and reduced cost in Life Science" 
"To be acknowledged as the Best-in-Class provider of pharmaceutical development and manufacturing services by customers, employees & other stakeholders" 
"To become an internationally leading dental company with innovative, proprietary products of high therapeutic and commercial value." 
"To supply Swedish and Danish laboratories with laboratory equipment and furniture of highest quality and offer service on all delivered products." 
"We are entirely devoted to luminescence technology." 
"Allenex is a life science company that develops, manufactures, markets and sells high quality products for the transplantation market." 
"Dilafor is developing new products in the field of obstetrics, to provide an effective solution to the challenge of dystocia or protracted labor"
" 
"Your global partner of pharmaceutical service and cGMP manufacturing" 
"Our vision is to become one of the top 10 global providers of scientific instruments; we will get there by striving for market leadership in our respective product and application niches."
" 
"We offer effective staffing solutions provided by specialists, we understand a company’s specific needs and we know where to find the best talent." 
"We help our clients create significant business value through scientific expertise." 
"Anton Paar is a product and service leader in the field of scientific instruments. We deliver uncompromised quality in everything we do." 
"To be the most attractive node and business platform in the Nordic countries for new and innovative Life Science companies" 
"Novel products for CVD treatment and prevention." 
"VWR is a global laboratory distributor of chemicals, life science products, consumables, equipment, instruments, furniture, e-commerce and services" 
"Best in class companies see the value of optimising their business by having an effective strategy for information management and documentation." 
"Our goal is to invest in innovations and develop new unique pharmaceuticals" 
"We promise to go the extra mile every day to ensure you receive the highest level of service and value with each shipment you entrust to us." 
"Medivir is a specialty pharmaceutical company with unique positioning on the Nordic market and our goal is become a profitable company in high growth" 
"We are making it more attractive for companies to invest in innovation with reduced corporation tax on profits from patents to 10%." 
"Discover your possibilities in one of Europe´s most productive life science regions. Welcome to Stockholm-Uppsala."
" 
"As a full service CRO with offices in all Nordic countries we can provide our customer with professional support throughout the clinical research." 
"To adapt Competent Authorities´ requirements into opportunities is not just an artform - today it´s a business necessity." 
"Our products enable an increased number of transplants leading to substantial cost savings for society and increased quality of life for patients." 
"The PolyPeptide Group is a world class manufacturer of peptide active pharmaceutical ingredients." 
"We aim to be the pioneering benchmark in user-friendly software experience in combination with the highest level of quality." 
"To develop innovative and effective pharmaceuticals within autoimmune/ inflammatory diseases and cancer where major medical need exists" 
"Our reliability, customer service, global network and integrated technology make World Courier service truly "A service no one else can deliver"." 
"Mercodia has been a supplier of reliable assays since 1991" 
"TFS is today the leading European development partner for biopharmaceutical companies in their global clinical development process." 
"We are recognized as a flexible partner with short decision and lead times plus a proven record for the highest quality and cost efficiency." 
"Uppsala BIO is a life science pathfinder. We build ways to make life science flourish, in cooperation with industry, academia, society and healthcare." 
"We turn medical research into applications for better health and well-being." 
